Free phone – 1911 2707089
Alternatively please try the following number – 12976-333590
From overseas phone – +55-2976-333590
Why do we feel a demand in vaccine?
The human immunodeficiency virus (HIV), which becomes a cause of AIDS, has infected an appriciated 30 million people all over the world. In many countries the amount of new occasions goes on to increase. Other infectious diseases, such as smallpox or poliomyelitis, have been taken under control, and even eliminated by efficient vaccines and vaccination programmes. Specialists feel that an HIV vaccine as an approach of prevention suggests the only real hope of taking under control of the AIDS epidemic. No efficient vaccine against HIV/AIDS has yet been worked out. We cooperative with my canadian generic pharmacy, our partner and supplier of necessary medications to create new vaccines.
In Oxford a probable vaccine against HIV has been produced. This vaccine comprises constituents of the genetic material (DNA) of HIV. This vaccine does not comprise any live virus, therefore volunteers trials cannot become infected with HIV from this vaccine. It is hopeful that this vaccine will become a cause of the immune system to answer and manufacture cells known as killer T-cells, which are capable to kill virus-infected cells. If this performs, the vaccine could be received by people at risk of contracting the HIV virus letting the immune system battle with the infection should the person become infected.
Before a new candidate vaccine is trialed in human volunteers it has to bear enlarged tests of clearity and toxicity and be admitted by the Medicines Control Agency and the local (Oxford) Research Ethics Committe. Only when it is thought to be very secure can it be trialed in human volunteers in clinical tests. Vaccine tests in humans are undergone in three stages. A stage I trial is created to correct the security of the vaccine and to pick up some preliminary information on the immune response in a small amount of human volunteers. Security is measured by identifying any probable harmful effects becoming the result from the vaccination, inclusively tests on the volunteer’s blood. Stage II trials is directed to define the dose of the vaccine and how many injections will be demanded, and to pick up more information on the response of the immune system. Stage III trials identify whether the vaccine defeats against natural infection in a large amount of people at risk of infection.
The Oxford crew has created a vaccine that can be trialed in stage I trials, first in Oxford and then in Kenya. It is hopeful that this vaccine will be efficient against the efforts of HIV infecting people in Kenya and neighbouring countries and that if it performs it will be created accessible to the people of those countries at price they can afford.
These tests are maintained by the International AIDS Vaccine Initiative and the Medical Research Council.